drugset / Trial / NCT01185015

A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization

NCT01185015

Phase 4 Withdrawn Merck KGaA, Darmstadt, Germany
NaSingle-groupOpen-labelTreatment

Summary

The multi-centric, open label, single arm and self controlled study is planned to assess the efficacy of orally administered Sigmart in subjects with recurrent angina after coronary revascularization. The primary objective of this study is to demonstrate that orally administered Sigmart can improve the major Exercise Tolerance Test (ETT) result in recurrent angina subjects.

Timeline

Start
2011-01
Primary completion
2011-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicorandil Other / unclassified 5 mg Oral

Indications

No indication recorded.